Infosys and Indivi Collaborate to Transform Neuroscience Drug Development with Digital Contract Research Organization Model

Infosys has announced a strategic collaboration with Indivi, a TechBio company transforming smartphones into precision medicine tools for neuroscience research and development. Together, they aim to revolutionize neuroscience drug development through an innovative Digital Contract Research Organization (CRO) model.

The collaboration combines Infosys’ global operational and technical capabilities, including artificial intelligence, machine learning, and wearable sensors with Indivi’s deep expertise in neuroscience and digital biomarker development for clinical research. It introduces a new approach to clinical trials, offering significant advancements in efficiency, scalability, and scientific accuracy for the development of drugs targeting complex neurological conditions like Parkinson’s and Alzheimer’s.

The Digital CRO model generates continuous and comprehensive data that goes beyond the limitations of traditional clinical trials’ subjective assessments. The approach addresses core industry challenges and creates richer data sets. This enables better endpoints, shorter drug development timelines, and improved success rates. With its application across all stages of therapy development – from early proof-of-concept validation to large-scale Phase III studies for regulatory approval – the model fosters a pathway to bring therapies to market more effectively.

In addition, this approach integrates essential functions that are fragmented in traditional CRO models, such as regulatory services, device management, clinical and data science, as well as global program execution. Leveraging an AI-powered data core, Infosys will support Indivi in addressing key gaps in the current clinical trial landscape, ensuring seamless operations and superior outcomes.

This collaboration further underscores Infosys’ commitment to applying cutting-edge digital capabilities to advance the life sciences sector. By rethinking the clinical trial paradigm, Infosys and Indivi aim to help the industry accelerate the availability of innovative therapies for patients.